𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study

✍ Scribed by Rudolph M. Navari; Lawrence H. Einhorn; Steven D. Passik; Patrick J. Loehrer; Cynthia Johnson; M. L. Mayer; J. McClean; Jake Vinson; W. Pletcher

Publisher
Springer-Verlag
Year
2005
Tongue
English
Weight
97 KB
Volume
13
Category
Article
ISSN
0941-4355

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Ondasetron versus granisetron in the pre
Ondasetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial
✍ Vittorio Gebbia; Giuseppe Cannata; Antonio Testa; Giuseppina Gurto; Roberto Vale πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 731 KB

Background. A single-institution, prospective, randomized open trial was performed to compare ondansetron and granisetron in the prevention of chemotherapyrelated nausea and vomiting. The effect of antemetic drugs was analyzed indipendently for patients treated with highly emetogenic chemotherapy (S

A phase I study of a new 5HT3-receptor a
A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting
✍ Geoffrey Falkson; Adriaan J. Zyl πŸ“‚ Article πŸ“… 1989 πŸ› Springer 🌐 English βš– 370 KB

In a phase I study of BRL43694A, a 5HT3-receptor antagonist, a single dose of 40 micrograms/kg was given to 24 patients. All patients received cytostatic treatment expected to cause nausea and vomiting. During the first 24 h, 12 patients were completely protected from nausea and vomiting, 4 experien